» Articles » PMID: 34944840

Plant Derived Bioactive Compounds, Their Anti-Cancer Effects and Approaches As an Alternative Target Treatment Strategy for Breast Cancer: An Updated Overview

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Dec 24
PMID 34944840
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is one of the most common malignant diseases that occur worldwide, among which breast cancer is the second leading cause of death in women. The subtypes are associated with differences in the outcome and were selected for treatments according to the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor. Triple-negative breast cancer, one of the subtypes of breast cancer, is difficult to treat and can even lead to death. If breast cancer is not treated during the initial stages, it may spread to nearby organs, a process called metastasis, through the blood or lymph system. For in vitro studies, MCF-7, MDA-MB-231, MDA-MB-468, and T47B are the most commonly used breast cancer cell lines. Clinically, chemotherapy and radiotherapy are usually expensive and can also cause side effects. To overcome these issues, medicinal plants could be the best alternative for chemotherapeutic drugs with fewer side effects and cost-effectiveness. Furthermore, the genes involved in breast cancer can be regulated and synergized with signaling molecules to suppress the proliferation of breast cancer cells. In addition, nanoparticles encapsulating (nano-encapsulation) medicinal plant extracts showed a significant reduction in the apoptotic and cytotoxic activities of breast cancer cells. This present review mainly speculates an overview of the native medicinal plant derived anti-cancerous compounds with its efficiency, types and pathways involved in breast cancer along with its genes, the mechanism of breast cancer brain metastasis, chemoresistivity and its mechanism, bioinformatics approaches which could be an effective alternative for drug discovery.

Citing Articles

Exploring Herbal Compounds as Targeted Therapies for Breast Cancer: Insights from Network Pharmacology, Molecular Docking, MD Simulation, ADME-Toxicity and DFT Profiles.

Zhang H Iran J Pharm Res. 2025; 23(1):e153579.

PMID: 40066125 PMC: 11892757. DOI: 10.5812/ijpr-153579.


Identification of Novel Progesterone Receptor (PR) Inhibitors () from Metabolites of Biotransformation Fungal: A Bioinformatics Approach.

Dourado J, Lopes S, Jimenez D, Ramos R, Ferreira I Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005951 PMC: 11858247. DOI: 10.3390/ph18020136.


Comprehensive pharmacokinetic profiling and molecular docking analysis of natural bioactive compounds targeting oncogenic biomarkers in breast cancer.

Othman B, Beigh S, Albanghali M, Sindi A, Shanawaz M, Ibahim M Sci Rep. 2025; 15(1):5426.

PMID: 39948091 PMC: 11825887. DOI: 10.1038/s41598-024-84401-4.


Bioactive Molecules, Ethnomedicinal Uses, Toxicology, and Pharmacology of Sond (Fabaceae): Systematic Review.

Mongalo N, Raletsena M Plants (Basel). 2025; 14(2).

PMID: 39861592 PMC: 11768249. DOI: 10.3390/plants14020239.


Current Combinatorial Therapeutic Aspects: The Future Prospect for Glioblastoma Treatment.

Gautam M, Gabrani R Curr Med Sci. 2024; 44(6):1175-1184.

PMID: 39695017 DOI: 10.1007/s11596-024-2950-7.


References
1.
Shobha N, Nanda N, Shivanna Giresha A, Manjappa P, P S, Dharmappa K . Synthesis and characterization of Zinc oxide nanoparticles utilizing seed source of Ricinus communis and study of its antioxidant, antifungal and anticancer activity. Mater Sci Eng C Mater Biol Appl. 2019; 97:842-850. DOI: 10.1016/j.msec.2018.12.023. View

2.
Hui M, Cazet A, Nair R, Watkins D, OToole S, Swarbrick A . The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. Breast Cancer Res. 2013; 15(2):203. PMC: 3672663. DOI: 10.1186/bcr3401. View

3.
Wang J, Li Y, Yang Y, Du J, Zhao M, Lin F . Systems Pharmacology Dissection of Multiscale Mechanisms of Action for Herbal Medicines in Treating Rheumatoid Arthritis. Mol Pharm. 2017; 14(9):3201-3217. DOI: 10.1021/acs.molpharmaceut.7b00505. View

4.
Schettini F, Prat A . Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast. 2021; 59:339-350. PMC: 8374722. DOI: 10.1016/j.breast.2021.07.019. View

5.
Mohinta S, Wu H, Chaurasia P, Watabe K . Wnt pathway and breast cancer. Front Biosci. 2007; 12:4020-33. DOI: 10.2741/2368. View